{"id":"W4411332234","doi":"10.1002/hon.70093_134","title":"134 | EFFICACY AND SAFETY OF FIRST‐LINE IBRUTINIB PLUS VENETOCLAX IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO WERE OLDER OR HAD TP53 MUTATIONS IN THE SYMPATICO STUDY","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital; Queen Elizabeth II Health Sciences Centre","funders":"Pharmacyclics","keywords":"Ibrutinib; Mantle cell lymphoma; Venetoclax; Lymphoma; Medicine; Cancer research; Oncology; Internal medicine; Leukemia; Chronic lymphocytic leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001403264,0.0005965886,0.00117186,0.0002287399,0.0002234349,0.0006740328,0.0003876797,0.0005351331,0.003101696],"category_scores_gemma":[0.0007104449,0.0002649116,0.001482584,0.0003130411,0.0003055338,0.0004654238,0.0002975616,0.001889013,0.000368117],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00045883,"about_ca_system_score_gemma":0.0006503029,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004655689,"about_ca_topic_score_gemma":0.001756835,"domain_scores_codex":[0.9996626,0.0001618563,0.00002791035,0.00005422546,0.00004434749,0.00004907509],"domain_scores_gemma":[0.9995371,0.0001042241,0.0001222565,0.000038597,0.00003449475,0.0001634276],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8059042,0.01254479,0.03249171,0.001612935,0.003855733,0.0002362441,0.0001545518,0.001305379,0.02238126,0.0002202728,0.008192247,0.1111007],"study_design_scores_gemma":[0.538829,0.3226002,0.1234365,0.0001468293,0.002966557,0.0005688854,0.00008239126,0.00145997,0.002526062,0.0002793687,0.007044745,0.00005955846],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9908886,0.004215778,0.0002132764,0.0003395015,0.0001631104,0.000358297,0.001513795,0.00003715506,0.002270483],"genre_scores_gemma":[0.9937616,0.001186568,0.0003525166,0.000521042,0.0002289134,0.0003252712,0.002698524,0.000008041116,0.0009174598],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003101696,"threshold_uncertainty_score":0.01037621,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02185390775549227,"score_gpt":0.3318345856293453,"score_spread":0.309980677873853,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}